Recent preclinical studies demonstrate that IL‐6/JAK‐STAT3 axis inhibition reduces myeloma cell viability while normalizing inflammation‐associated metabolic disturbances, supporting its therapeutic potential in precursor states [25, 32]. This evidence concerns the gene IL6 and plasma cell myeloma.